title: Exocrine pancreatic insufficiency following esophagectomy.
abstract: Weight loss following esophagectomy is a management challenge for all patients. It is multifactorial with contributing factors including loss of gastric reservoir, rapid small bowel transit, malabsorption, and adjuvant chemotherapy. The development of a postoperative malabsorption syndrome, as a result of exocrine pancreatic insufficiency (EPI), is recognized in a subgroup of patients following gastrectomy. This has not previously been documented following esophageal resection. EPI can result in symptoms of flatulence, diarrhea, steatorrhea, vitamin deficiencies, and weight loss. It therefore has the potential to pose a significant level of morbidity in postoperative patients. There is some evidence that patients with proven EPI (fecal elastase-1 < 200 μg/g) may benefit from a trial of pancreatic enzyme replacement therapy (PERT). We observed symptoms compatible with EPI in a subgroup of patients following esophagectomy. We hypothesized that this was contributing to malabsorption and malnutrition in these patients. To investigate this, fecal elastase-1 was measured in postoperative patients, and in those with proven EPI, a trial of PERT was commenced in combination with specialist dietary education. At routine postoperative follow-up, which included assessment by a specialist dietitian, those patients with symptoms suggestive of malabsorption were given the opportunity to have their fecal elastase-1 measured. PERT was then offered to patients with fecal elastase-1 less than 200 μg/g (EPI) as well as those in the 200-500 μg/g range (mild EPI) with more severe symptoms. Fecal elastase-1 was measured in 63 patients between June 2009 and January 2011 at a median of 4 months (range 1-42) following surgery. Ten patients had fecal elastase-1 less than 200 μg/g, and all had failed to maintain preoperative weight. All accepted a trial of PERT. Nine (90%) had symptomatic improvement, and seven (70%) increased their weight. Thirty-nine patients had a fecal elastase-1 in the 200-500 μg/g range. Twelve were given a trial of PERT based on level of symptoms, five (42%) reported an improvement in symptoms, but only two (17%) gained weight. Our early results support the observation that EPI is a factor contributing to postoperative morbidity in patients recovering from esophagectomy and that these patients can benefit from a trial of PERT. Our study has limitations, and a formal trial is required to evaluate the impact of EPI and PERT following esophagectomy. Currently, our practice is to measure fecal elastase-1 in any patient with unexplained weight loss or symptoms of malabsorption. In patients with proven EPI or those who are symptomatic with mild EPI, a trial of PERT should be offered and symptoms reassessed.
authors.affiliation: Regional Oesophagogastric Unit, Royal Surrey County Hospital, Guildford, Surrey, UK.
authors.forename: J R
authors.initials: JR
authors.lastname: Huddy
authors.forename: F M S
authors.initials: FM
authors.lastname: Macharg
authors.forename: A M
authors.initials: AM
authors.lastname: Lawn
authors.forename: S R
authors.initials: SR
authors.lastname: Preston
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002352:Carrier Proteins / Q000032:analysis; D010450:Endopeptidases / Q000032:analysis; D056947:Enzyme Replacement Therapy / Q000379:methods; D016629:Esophagectomy / Q000009:adverse effects*; D010188:Exocrine Pancreatic Insufficiency / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005243:Feces / Q000201:enzymology; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D008286:Malabsorption Syndromes / Q000209:etiology; D008297:Male; D044342:Malnutrition / Q000209:etiology; D008875:Middle Aged; D044623:Nutrition Therapy; D010196:Pancreatic Elastase; D010194:Pancreatin / Q000627:therapeutic use; D020799:Pancrelipase / Q000627:therapeutic use; D010865:Pilot Projects; D011183:Postoperative Complications; D016896:Treatment Outcome; D015430:Weight Gain; D015431:Weight Loss
chemical_list: D002352:Carrier Proteins; D005765:Gastrointestinal Agents; D020799:Pancrelipase; D010194:Pancreatin; D010450:Endopeptidases; D010196:Pancreatic Elastase; C017130:cholesterol-binding protein